They indicated that anti-SOST-IgG might be used as a potential biomarker in axial SpA in patients with IBD, in addition, the presence of anti-SOST-IgG and reduction of SOST might be used as a new target in the study of SPA pathogenesis. Here, SOST is linked to inflammatory bowel disease.